{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T05:03:35Z","timestamp":1700283815928},"reference-count":38,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2004,5,24]],"date-time":"2004-05-24T00:00:00Z","timestamp":1085356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2004,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Over the past century, a worldwide system for the control of drugs with abuse potential has developed through the adoption of a series of international treaties. The important multilateral conventions currently in force are the United Nations Single Convention on Narcotic Drugs, 1961 (Single Convention), the United Nations Convention on Psychotropic Substances, 1971 (Psychotropic Convention) and the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988. From the beginning, the aim of these drug control treaties has been to control the abuse and trafficking of substances with abuse potential while assuring that the availability of these drugs for medical and scientific purposes is not unduly restricted.<\/jats:p><jats:p>There is activity in the World Health Organization and the International Narcotics Control Board to determine whether the international control of buprenorphine, a partial mu\u2010opioid agonist used as an analgesic and for the treatment of opioid addiction, should be changed from the Psychotropic Convention to the Single Convention. This change would result in the classification and regulation of buprenorphine as a narcotic drug rather than a psychotropic substance. Such a move is unwarranted medically and scientifically and would provoke increased controls on buprenorphine that would fundamentally disrupt the medical practice of pain management and opioid replacement therapy around the world. The negative impact of inappropriate regulatory controls when licensed medicines come under such scrutiny are described. Copyright \u00a9 2004 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hup.588","type":"journal-article","created":{"date-parts":[[2004,5,24]],"date-time":"2004-05-24T11:05:09Z","timestamp":1085396709000},"page":"215-224","source":"Crossref","is-referenced-by-count":3,"title":["Medicines and the drug control treaties: is buprenorphine for opioid addiction at risk of being lost?"],"prefix":"10.1002","volume":"19","author":[{"given":"J. A.","family":"Costa e Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,5,24]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.1.39"},{"key":"e_1_2_1_3_1","unstructured":"Convention on Psychotropic Substances.1971.http:\/\/www.incb. org\/e\/ind_conv.htm"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.268.10.1306"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.378"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1977.tb07532.x"},{"key":"e_1_2_1_7_1","unstructured":"Drug Addiction Treatment Act of 2000 P.L. 106\u2013310 \u00a7\u00a7 3501\u201002 114 Stat. 1222 (codified as amended at 21 U.S.C. \u00a7 823(g) (2000))."},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1981.tb10473.x"},{"key":"e_1_2_1_9_1","unstructured":"FelterHW LloydJU.1898.King's American Dispensatory.http:\/\/www.ibiblio.org\/herbmed\/eclectic\/kings\/intro.html"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07150-5"},{"key":"e_1_2_1_11_1","first-page":"295","volume-title":"Opiates and Endogenous Opioid Peptides","author":"Hambrook JM","year":"1976"},{"key":"e_1_2_1_12_1","unstructured":"International Narcotics Control Board.1995.Report of The International Narcotics Control Board for 1995. United Nations.http:\/\/www.incb.org\/e\/ind_ar.htm"},{"key":"e_1_2_1_13_1","unstructured":"International Narcotics Control Board.1999.Report of The International Narcotics Control Board for 1999 Para 155 361. United Nations.http:\/\/www.incb.org\/e\/ind_ar.htm"},{"key":"e_1_2_1_14_1","unstructured":"International Narcotics Control Board.2000.Report of the International Narcotics Control Board for 2000 Para 171. United Nations.http:\/\/www.incb.org\/e\/ind_ar.htm"},{"key":"e_1_2_1_15_1","unstructured":"International Narcotics Control Board.2001.Report of the International Narcotic Control Board for 2001 Para 429. United Nations.http:\/\/www.incb.org\/e\/ind_ar.htm"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0379-0738(01)00454-6"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(87)90112-2"},{"key":"e_1_2_1_18_1","first-page":"517","article-title":"The effects of morphine\u2010 and nalorphine\u2010like drugs in the nondependent and morphine\u2010dependent chronic spinal dog","volume":"197","author":"Martin WR","year":"1976","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199309030-00001"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00442021"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2001.96226710.x"},{"key":"e_1_2_1_22_1","unstructured":"Office of National Drug Control Policy.2003.Fact Sheet. Heroin. Drug Policy Information Clearinghouse.www.whitehousedrugpolicy.gov."},{"key":"e_1_2_1_23_1","unstructured":"Office of National Drug Control Policy.2000.Fact Sheet. Methadone. Drug Policy Information Clearinghouse.www.whitehousedrugpolicy.gov."},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1991.116"},{"key":"e_1_2_1_25_1","first-page":"382","article-title":"An empirical review of the impact of triplicate prescription of benzodiazepines","volume":"43","author":"Schwartz HI","year":"1992","journal-title":"Hosp Community Psychiatry"},{"key":"e_1_2_1_26_1","unstructured":"Single Convention on Narcotic Drugs 1961 as amended by the 1972 Protocol Amending the Single Convention on Narcotic Drugs 1961.http:\/\/www.incb.org\/e\/ind_conv.htm"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1003-8"},{"key":"e_1_2_1_28_1","unstructured":"United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances 1988.http:\/\/www.incb.org\/e\/ind_conv.htm."},{"key":"e_1_2_1_29_1","unstructured":"United Nations.2003.Psychotropic Substances Statistics for 2001. INCB Technical Report E\/INCB\/2002\/3. Schedule III. B\u20103. Imports."},{"key":"e_1_2_1_30_1","first-page":"361","article-title":"Acute administration of buprenorphine in humans: partial agonist and blockade effects","volume":"274","author":"Walsh SL","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.71"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1991.03470170080028"},{"key":"e_1_2_1_33_1","unstructured":"WHO Expert Committee on Drug Dependence.1989. Twenty\u2010fifth Report.WHO Technical Report Series 775. World Health Organization: Geneva."},{"key":"e_1_2_1_34_1","unstructured":"WHO Expert Committee on Drug Dependence.1996. Thirtieth report.WHO Technical Report Series No. 873. World Health Organization: Geneva."},{"key":"e_1_2_1_35_1","unstructured":"WHO Expert Committee on Drug Dependence.2003. Thirty\u2010third Report.WHO Technical Report Series No. 915. World Health Organization: Geneva."},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)90902-2"},{"key":"e_1_2_1_37_1","unstructured":"World Health Organization.2000a.Narcotic and Psychotropic Drugs: Achieving Balance in National Opioids Control Policy. Guidelines For Assessment. WHO\/EDM\/QSM\/2000.4."},{"key":"e_1_2_1_38_1","unstructured":"World Health Organization.2000b.Guidelines for the WHO review of dependence\u2010producing psychoactive substances for international control. EB 105\/2000\/REC\/1 Annex 9."},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002809202600417"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.588","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.588","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:07:53Z","timestamp":1700266073000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,24]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["10.1002\/hup.588"],"URL":"https:\/\/doi.org\/10.1002\/hup.588","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5,24]]}}}